Novavax Historical Income Statement
| NVAX Stock | USD 4.07 0.10 2.52% |
Historical analysis of Novavax income statement accounts such as Total Revenue of 1 B can show how well Novavax performed in making a profits. Evaluating Novavax income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Novavax's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Novavax latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Novavax is a good buy for the upcoming year.
Novavax |
About Novavax Income Statement Analysis
Novavax Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Novavax shareholders. The income statement also shows Novavax investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Novavax Income Statement Chart
Novavax Income Statement is one of the three primary financial statements used for reporting Novavax's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Novavax revenue and expense. Novavax Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Novavax's Depreciation And Amortization is fairly stable compared to the past year. Interest Expense is likely to rise to about 15.1 M in 2024, despite the fact that Operating Income is likely to grow to (394.3 M). Add Fundamental
Total Revenue
Total revenue comprises all receipts Novavax generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Novavax. It is also known as Novavax overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from Novavax's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Novavax current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.At this time, Novavax's Depreciation And Amortization is fairly stable compared to the past year. Interest Expense is likely to rise to about 15.1 M in 2024, despite the fact that Operating Income is likely to grow to (394.3 M).
Novavax income statement Correlations
Click cells to compare fundamentals
Novavax Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Novavax income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | (18.0M) | 4.9M | 12.7M | 11.0M | 41.2M | 43.3M | |
| Selling General Administrative | 34.4M | 145.3M | 298.4M | 488.7M | 475.4M | 499.1M | |
| Total Revenue | 18.7M | 475.6M | 1.1B | 1.6B | 983.7M | 1.0B | |
| Gross Profit | (95.2M) | 475.6M | 1.1B | 696.3M | 704.2M | 739.4M | |
| Other Operating Expenses | 148.3M | 892.3M | 2.8B | 2.2B | 1.4B | 1.5B | |
| Operating Income | (120.6M) | (416.7M) | (1.7B) | (644.7M) | (415.0M) | (394.3M) | |
| Ebit | (120.6M) | (416.7M) | (1.7B) | (644.7M) | (415.0M) | (394.3M) | |
| Research Development | 113.8M | 747.0M | 2.5B | 1.2B | 656.0M | 688.8M | |
| Ebitda | (138.6M) | (411.8M) | (1.7B) | (633.8M) | (373.8M) | (355.1M) | |
| Cost Of Revenue | 113.8M | 747.0M | 12.7M | 902.6M | 279.5M | 293.4M | |
| Total Operating Expenses | 148.3M | 892.3M | 2.8B | 1.3B | 1.1B | 1.2B | |
| Income Before Tax | (132.7M) | (418.3M) | (1.7B) | (653.6M) | (543.0M) | (515.9M) | |
| Total Other Income Expense Net | (12.1M) | (1.5M) | (28.0M) | (8.9M) | (128.0M) | (121.6M) | |
| Net Income | (130.1M) | (427.5M) | (1.7B) | (657.9M) | (545.1M) | (517.8M) | |
| Income Tax Expense | (2.6M) | 9.2M | 29.2M | 4.3M | 2.0M | 1.8M | |
| Net Income From Continuing Ops | (132.7M) | (418.3M) | (1.7B) | (657.9M) | (548.9M) | (576.4M) | |
| Non Operating Income Net Other | 2.8M | 1.5M | 13.6M | (6.8M) | (7.9M) | (7.5M) | |
| Net Income Applicable To Common Shares | (132.7M) | (418.3M) | (1.7B) | (657.9M) | (592.1M) | (562.5M) | |
| Reconciled Depreciation | 5.7M | 4.9M | 12.7M | 29.1M | 37.7M | 39.5M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.Note that the Novavax information on this page should be used as a complementary analysis to other Novavax's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Complementary Tools for Novavax Stock analysis
When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities |
Is Novavax's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novavax. If investors know Novavax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novavax listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.41) | Revenue Per Share 9.762 | Quarterly Revenue Growth (0.18) | Return On Assets (0.17) | Return On Equity (8.98) |
The market value of Novavax is measured differently than its book value, which is the value of Novavax that is recorded on the company's balance sheet. Investors also form their own opinion of Novavax's value that differs from its market value or its book value, called intrinsic value, which is Novavax's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novavax's market value can be influenced by many factors that don't directly affect Novavax's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novavax's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novavax is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novavax's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.